Lupin launches Mesalamine Extended-Release Capsules 0.375 g in US market
Mesalamine Extended-Release Capsules 0.375 g (authorized generic version) are indicated for the maintenance of remission of ulcerative colitis in patients 18 years of age and older.
Mesalamine Extended-Release Capsules 0.375 g, RLD: Apriso had an annual sales of approximately USD 290 million in the U.S. (IQVIA MAT March 2020).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content